tetano
Editor, Senior Moderator
Virology
. 2020 Dec 29;554:97-105.
doi: 10.1016/j.virol.2020.12.013. Online ahead of print.
Neutralizing antibody-dependent and -independent immune responses against SARS-CoV-2 in cynomolgus macaques
Hirohito Ishigaki[SUP] 1 [/SUP], Misako Nakayama[SUP] 1 [/SUP], Yoshinori Kitagawa[SUP] 2 [/SUP], Cong Thanh Nguyen[SUP] 1 [/SUP], Kaori Hayashi[SUP] 3 [/SUP], Masanori Shiohara[SUP] 1 [/SUP], Bin Gotoh[SUP] 1 [/SUP], Yasushi Itoh[SUP] 4 [/SUP]
Affiliations
Abstract
We examined the pathogenicity of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in cynomolgus macaques for 28 days to establish an animal model of COVID-19 for the development of vaccines and antiviral drugs. Cynomolgus macaques infected with SARS-CoV-2 showed body temperature rises and X-ray radiographic pneumonia without life-threatening clinical signs of disease. A neutralizing antibody against SARS-CoV-2 and T-lymphocytes producing interferon (IFN)-γ specifically for SARS-CoV-2 N-protein were detected on day 14 in one of three macaques with viral pneumonia. In the other two macaques, in which a neutralizing antibody was not detected, T-lymphocytes producing IFN-γ specifically for SARS-CoV-2 N protein increased on day 7 to day 14, suggesting that not only a neutralizing antibody but also cellular immunity has a role in the elimination of SARS-CoV-2. Thus, because of similar symptoms to approximately 80% of patients, cynomolgus macaques are appropriate to extrapolate the efficacy of vaccines and antiviral drugs for humans.
Keywords: Neutralizing antibody; Nonhuman primate; Pneumonia; SARS-CoV-2; Th1 response; Thrombus.
. 2020 Dec 29;554:97-105.
doi: 10.1016/j.virol.2020.12.013. Online ahead of print.
Neutralizing antibody-dependent and -independent immune responses against SARS-CoV-2 in cynomolgus macaques
Hirohito Ishigaki[SUP] 1 [/SUP], Misako Nakayama[SUP] 1 [/SUP], Yoshinori Kitagawa[SUP] 2 [/SUP], Cong Thanh Nguyen[SUP] 1 [/SUP], Kaori Hayashi[SUP] 3 [/SUP], Masanori Shiohara[SUP] 1 [/SUP], Bin Gotoh[SUP] 1 [/SUP], Yasushi Itoh[SUP] 4 [/SUP]
Affiliations
- PMID: 33412411
- PMCID: PMC7771262
- DOI: 10.1016/j.virol.2020.12.013
Abstract
We examined the pathogenicity of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in cynomolgus macaques for 28 days to establish an animal model of COVID-19 for the development of vaccines and antiviral drugs. Cynomolgus macaques infected with SARS-CoV-2 showed body temperature rises and X-ray radiographic pneumonia without life-threatening clinical signs of disease. A neutralizing antibody against SARS-CoV-2 and T-lymphocytes producing interferon (IFN)-γ specifically for SARS-CoV-2 N-protein were detected on day 14 in one of three macaques with viral pneumonia. In the other two macaques, in which a neutralizing antibody was not detected, T-lymphocytes producing IFN-γ specifically for SARS-CoV-2 N protein increased on day 7 to day 14, suggesting that not only a neutralizing antibody but also cellular immunity has a role in the elimination of SARS-CoV-2. Thus, because of similar symptoms to approximately 80% of patients, cynomolgus macaques are appropriate to extrapolate the efficacy of vaccines and antiviral drugs for humans.
Keywords: Neutralizing antibody; Nonhuman primate; Pneumonia; SARS-CoV-2; Th1 response; Thrombus.